A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

Abstract

AngQb reduces blood pressure in SHR to levels obtained with an ACE inhibitor, and is immunogenic and well tolerated in humans. Therefore, vaccination against angiotensin II has the potential to become a useful antihypertensive treatment providing long-lasting effects and improving patient compliance.